Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $42.25.

Several research firms recently issued reports on VOR. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings cut Vor Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. HC Wainwright reissued a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Finally, Wedbush increased their price target on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, May 14th.

Vor Biopharma Stock Down 2.3%

VOR stock opened at $14.50 on Friday. Vor Biopharma has a 12-month low of $5.80 and a 12-month high of $65.80. The stock’s 50 day simple moving average is $14.78 and its 200 day simple moving average is $14.31.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Vor Biopharma will post -2.51 earnings per share for the current year.

Insider Buying and Selling at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 589,257 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the transaction, the director directly owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. This represents a 11.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 3,002,903 shares of company stock worth $49,412,176. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. RA Capital Management L.P. lifted its holdings in shares of Vor Biopharma by 172.7% during the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after buying an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. increased its stake in shares of Vor Biopharma by 852.8% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Vor Biopharma in the 4th quarter worth $33,275,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Vor Biopharma in the 4th quarter worth $22,890,000. Finally, NEXTBio Capital Management LP purchased a new stake in shares of Vor Biopharma in the 4th quarter worth $13,080,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).